



LYC HEALTHCARE BERHAD

Registration No: 200401009170 (647673-A)

Incorporated in Malaysia

**QUARTERLY REPORT FOR SECOND QUARTER ENDED
30 SEPTEMBER 2024**

LYC HEALTHCARE BERHAD
Registration No: 200401009170 (647673-A)
Incorporated in Malaysia

The Board of Directors of LYC Healthcare Berhad (“LYC” or “Group”) hereby announce the following unaudited results which should be read in conjunction with the Audited Financial Statements of LYC for the financial year ended 31 March 2024 and the accompanying explanatory notes attached to the interim financial statements.

	Note	INDIVIDUAL QUARTER		CUMULATIVE QUARTERS	
		Current Year Quarter	Preceding Year Corresponding Quarter	Current Year to Date	Preceding Year Corresponding Period
		30-Sep-24	30-Sep-23	30-Sep-24	30-Sep-23
		RM'000	RM'000	RM'000	RM'000
Revenue	A8	41,735	32,401	81,113	59,031
Cost of sales		(18,908)	(14,335)	(37,007)	(27,162)
Gross profit		22,827	18,066	44,106	31,869
Other operating income		672	1,389	1,184	3,759
Operating expenses		(19,321)	(18,842)	(39,426)	(31,929)
Profit from operations	B5	4,178	613	5,864	3,699
Interest income		69	107	143	222
Interest expense		(2,624)	(2,256)	(5,087)	(4,644)
Share of result of associate and joint venture, net of tax		(74)	(507)	(99)	(911)
Profit/(Loss) before tax		1,549	(2,043)	821	(1,634)
Taxation	B6	(1,123)	(970)	(2,346)	(1,997)
Profit/(Loss) for the financial period		426	(3,013)	(1,525)	(3,631)
Other comprehensive income					
Foreign currency translation		(3,679)	(8)	(835)	(193)
Total comprehensive profit/(loss) for the financial period		(3,253)	(3,021)	(2,360)	(3,824)
Profit/(Loss) attributable to:					
Owners of the Company		(2,768)	(4,244)	(6,190)	(6,440)
Non-controlling interest		3,194	1,231	4,665	2,809
		426	(3,013)	(1,525)	(3,631)
Total comprehensive profit/(loss) attributable to:					
Owners of the Company		(5,600)	(4,249)	(8,583)	(6,440)
Non-controlling interest		2,347	1,228	6,223	2,616
		(3,253)	(3,021)	(2,360)	(3,824)
Loss per share attributable to Owners of the Company:					
Basic loss per share (sen)	B12(a)	(0.42)	(0.65)	(0.94)	(0.99)
Diluted loss per share (sen)	B12(b)	N/A	N/A	N/A	N/A

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2024

	AS AT 30-Sep-24 (UNAUDITED) RM'000	AS AT 31-Mar-24 (AUDITED) RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	46,817	48,405
Investment properties	3,245	3,251
Intangible assets	84,191	85,152
Right-of-use assets	57,547	42,801
Investment in an associate	713	812
Deferred tax assets	34	41
	<u>192,547</u>	<u>180,462</u>
Current assets		
Inventories	9,473	10,141
Trade and other receivables	26,932	26,562
Current tax assets	180	857
Amount due from joint venture & associate	1	-
Contract assets	-	122
Cash and bank balances	20,256	24,705
	<u>56,842</u>	<u>62,387</u>
TOTAL ASSETS	<u>249,389</u>	<u>242,849</u>
EQUITY AND LIABILITIES		
Equity attributable to owners of the Company		
Share capital	101,443	101,443
Other reserves	3,888	4,773
Accumulated losses	(73,431)	(67,241)
	<u>31,900</u>	<u>38,975</u>
Non-controlling interest	42,150	38,557
TOTAL EQUITY	<u>74,050</u>	<u>77,532</u>
Non-current liabilities		
Loan and borrowings	B8 23,381	21,638
Lease liabilities	46,649	36,903
Provision for restoration cost	2,441	2,011
Deferred tax liabilities	1,205	1,369
	<u>73,676</u>	<u>61,921</u>
Current liabilities		
Trade and other payables	27,122	26,907
Contract liabilities	6,087	6,874
Loan and borrowings	B8 56,287	54,197
Lease liabilities	8,982	8,893
Provision for annual wage supplement	155	345
Non controlling shareholder/director of a subsidiary	1,897	4,983
Current tax liabilities	1,133	1,197
TOTAL LIABILITIES	<u>175,339</u>	<u>165,317</u>
TOTAL EQUITY AND LIABILITIES	<u>249,389</u>	<u>242,849</u>
Net assets per share attributable to owners of the Company (RM)	<u>0.04</u>	<u>0.05</u>

**STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2024**

Group	← Attributable to owners of the Company →				Equity attributable to owners of the Company RM'000	Non- controlling interests RM'000	Total equity RM'000
	Share capital RM'000	Translation reserve RM'000	Revaluation reserve RM'000	Accumulated losses RM'000			
At 1 April 2024	101,443	4,345	428	(67,241)	38,975	38,557	77,532
Other comprehensive income, net of tax							
Foreign currency translation differences for foreign operations	-	(886)	1	-	(885)	50	(835)
Other comprehensive loss	-	(886)	1	-	(885)	50	(835)
Net loss for the financial period	-	-	-	(6,190)	(6,190)	4,665	(1,525)
Total comprehensive loss for the financial period	-	(886)	1	(6,190)	(7,075)	4,715	(2,360)
Transaction with owners:							
Disposal of non-controlling interests	-	-	-	-	-	(199)	(199)
Dividend paid to non-controlling interest	-	-	-	-	-	(923)	(923)
Total transactions with owners	-	-	-	-	-	(1,122)	(1,122)
At 30 September 2024	101,443	3,459	429	(73,431)	31,900	42,150	74,050

**STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2024**

Group	← Attributable to owners of the Company →				Equity attributable to owners of the Company RM'000	Non- controlling interests RM'000	Total equity RM'000
	Share capital RM'000	Translation reserve RM'000	Revaluation reserve RM'000	Accumulated losses RM'000			
At 1 April 2023	90,558	3,940	428	(48,016)	46,910	33,693	80,603
Other comprehensive income, net of tax							
Foreign currency translation differences for foreign operations	-	405	-	-	405	1,479	1,884
Other comprehensive income	-	405	-	-	405	1,479	1,884
Net loss for the financial year	-	-	-	(19,160)	(19,160)	4,256	(14,904)
Total comprehensive income/(loss) for the financial year	-	405	-	(19,160)	(18,755)	5,735	(13,020)
Transaction with owners:							
Issue of ordinary share pursuant to : - private placement	10,885	-	-	-	10,885	-	10,885
Acquisition of shares from non-controlling interest	-	-	-	(97)	(97)	(23)	(120)
Change in ownership interests in subsidiaries	-	-	-	32	32	368	400
Divestment	-	-	-	-	-	7	7
Non controlling interests arising from acquisition of subsidiaries	-	-	-	-	-	617	617
Dividend paid to non-controlling interest	-	-	-	-	-	(1,840)	(1,840)
Total transactions with owners	10,885	-	-	(65)	10,820	(871)	9,949
At 31 March 2024	101,443	4,345	428	(67,241)	38,975	38,557	77,532

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2024**

	30-Sep-24 (UNAUDITED)	31-Mar-24 (AUDITED)
	RM'000	RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit/(Loss) before tax	821	(10,827)
Adjustments for:		
Non-cash items	8,080	14,981
Interest income	(143)	(393)
Interest expense	5,087	9,199
Operating profit before Working Capital Changes	13,845	12,960
Changes In Working Capital:		
Net change in current assets	(154)	(8,118)
Net change in current liabilities	(646)	8,363
Net Cash Inflow from Operations	13,045	13,205
Income tax refund	245	100
Income tax paid	(1,750)	(4,156)
Net Operating Cash Flows	11,540	9,149
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	143	393
Advances to joint venture and associate	(1)	91
Acquisition of subsidiaries, net of cash acquired	-	(6,739)
Acquisition of equity interest from non-controlling interest	-	(120)
Subscription of shares in joint venture and associate	-	(4,117)
Placement of deposits with a licensed bank	-	(10,024)
Proceeds from disposal of Subsidiaries	380	-
Proceeds from disposal of property and equipment	-	465
Purchase of property, plant and equipment	(2,048)	(5,702)
Net Investing Cash Flows	(1,526)	(25,753)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from the issuance of private placement shares	-	10,885
Interest paid	(3,894)	(8,419)
Repayment of term loans & hire purchase	(2,555)	(2,228)
Payment on lease liabilities	(4,393)	(8,074)
Advances from non-controlling shareholder/directors of subsidiaries	(3,086)	(8,511)
Dividend paid to non-controlling interest	(923)	(1,840)
Proceeds from borrowings	454	562
Net Financing Cash Flows	(14,397)	(17,625)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(4,383)	(34,229)
Effects of foreign exchange rate changes	388	(1,250)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF FINANCIAL PERIOD/YEAR	4,174	39,653
CASH AND CASH EQUIVALENTS AT THE END OF FINANCIAL PERIOD/YEAR	179	4,174

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 SEPTEMBER 2024 (Cont'd)

	30-Sep-24 (UNAUDITED)	31-Mar-24 (AUDITED)
	RM'000	RM'000
CASH AND BANK BALANCES		
Cash on hand and at banks	10,174	12,985
Deposits placed with licensed banks	<u>10,082</u>	<u>11,720</u>
	20,256	24,705
Bank Overdraft	(9,995)	(9,956)
Less: Non-short term deposits	<u>(10,082)</u>	<u>(10,575)</u>
Cash and bank balances	<u>179</u>	<u>4,174</u>

PART A – EXPLANATORY NOTES PURSUANT TO MFRS 134: INTERIM FINANCIAL REPORTING AND IAS 34 : INTERIM FINANCIAL REPORTING

A1 – Accounting Policies and Basis of Preparation

The interim financial statements are unaudited and have been prepared in compliance with Malaysian Financial Reporting Standard (“MFRS”) 134: Interim Financial Reporting.

This report should be read in conjunction with the audited financial statements for the financial year ended 31 March 2024 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 31 March 2024.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Group with effect from 1 January 2024 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 31 March 2024. The adoption of these MFRSs does not have any material impact on the Group’s results and financial position.

A2 – Declaration on Audit Qualification

The latest audited financial statements for the financial year ended 31 March 2024 was not subject to any qualification.

A3 – Seasonal or Cyclicity of Operations

In general, apart from the Group’s business in Healthcare services, the Group’s other businesses are primarily exposed to business cycles of the Electronic Manufacturing, Semiconductor and Automotive industries.

A4 – Items of Unusual Nature, Size or Incidence

There were no other items of an unusual nature, size or incidence affecting the assets, liabilities, equity, net income or cash flows in the current financial year under review.

A5 – Changes in Estimates

There were no material changes in estimates of amounts reported in the prior financial year which may have had a material effect on the current financial year under review.

A6 – Debt and Equity Securities

There were no other issuances, cancellation, repurchases, resales and repayment of debts and equity securities during the current financial year under review other than as disclosed in note B7.

Pursuant to Rule 6.44(1) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, the effective date for the Share Grant Plan has been fixed on 19 September 2022.

There were no shares issued under the Company's share grant plan of up to 5% of the total number of issued shares of the Company (excluding treasury shares, if any).

A7 – Dividends

No dividends have been declared or paid during the current financial year under review.

A8 – Segmental Information

Segmental information in respect of the Group's business segments are as follows: -

- | | |
|---------------------------------------|---|
| i) Healthcare Services | Provision of mother and child care related services such as postnatal and postpartum care, post-delivery confinement care, and aesthetics, provision of healthcare related services, provision of cosmetics related services and medical aesthetic treatment, provision of child day care services, provision of medical and surgical advisory services, provision of dental treatment and consultancy services, provision of prostate cancer treatment, dealing in raw and finished, consumable and non-consumable food ingredients. |
| ii) Computing and Electronic Services | Performing research and development, and the provision of e-manufacturing solutions and IT outsourcing service, dealers of computers and other related products. |
| iii) Others | Investment holding and provision of management services. |

LYC HEALTHCARE BERHAD

Registration No: 200401009170 (647673-A)

Incorporated in Malaysia

A8 – Segmental Information (Cont'd)

a) Period ended 30 September 2024

	Healthcare Services RM'000	Computer Electronic Services RM'000	Others RM'000	Elimination RM'000	Total RM'000
Revenue	79,801	1,494	4,302	-	85,597
Inter-segment revenue	(409)	-	(4,075)	-	(4,484)
	<u>79,392</u>	<u>1,494</u>	<u>227</u>	<u>-</u>	<u>81,113</u>
Revenue					
Malaysia	49,844	1,494	226	-	51,564
Singapore	29,549	-	-	-	29,549
	<u>79,393</u>	<u>1,494</u>	<u>226</u>	<u>-</u>	<u>81,113</u>
Results	19,336	(46)	(5,286)	-	14,004
Interest income	-	143	-	-	143
Interest expense	(4,805)	(229)	(53)	-	(5,087)
Share of result of associate and joint venture	(99)	-	-	-	(99)
Depreciation & amortisation	(7,750)	(15)	(375)	-	(8,140)
Profit/(Loss) before tax	6,682	(147)	(5,714)	-	821
Taxation	(2,346)	-	-	-	(2,346)
Segment results after tax	<u>4,336</u>	<u>(147)</u>	<u>(5,714)</u>	<u>-</u>	<u>(1,525)</u>
Segment results before tax					
Malaysia	(1,485)	(131)	(2,686)	-	(4,302)
Singapore	8,167	(16)	(3,028)	-	5,123
	<u>6,682</u>	<u>(147)</u>	<u>(5,714)</u>	<u>-</u>	<u>821</u>

b) Period ended 30 September 2023

	Healthcare Services RM'000	Computer Electronic Services RM'000	Others RM'000	Elimination RM'000	Total RM'000
Revenue	58,136	1,811	147	-	60,094
Inter-segment revenue	(999)	(64)	-	-	(1,063)
	<u>57,137</u>	<u>1,747</u>	<u>147</u>	<u>-</u>	<u>59,031</u>
Revenue					
Malaysia	31,769	1,747	147	-	33,663
Singapore	25,368	-	-	-	25,368
	<u>57,137</u>	<u>1,747</u>	<u>147</u>	<u>-</u>	<u>59,031</u>
Result	14,755	(198)	(4,694)	-	9,863
Interest income	129	93	-	-	222
Interest expense	(4,602)	(8)	(34)	-	(4,644)
Share of result of associate and joint venture	(911)	-	-	-	(911)
Depreciation & amortisation	(5,893)	(15)	(256)	-	(6,164)
Profit/(Loss) before tax	3,478	(128)	(4,984)	-	(1,634)
Taxation	(1,997)	-	-	-	(1,997)
Segment results after tax	<u>1,481</u>	<u>(128)</u>	<u>(4,984)</u>	<u>-</u>	<u>(3,631)</u>
Segment results before tax					
Malaysia	(3,548)	(111)	(3,173)	-	(6,832)
Singapore	7,026	(17)	(1,811)	-	5,198
	<u>3,478</u>	<u>(128)</u>	<u>(4,984)</u>	<u>-</u>	<u>(1,634)</u>

A9 – Valuation of Property, Plant and Equipment

There was no valuation on any property, plant and equipment of the Group during current financial year under review.

A10 – Changes in Composition of the Group

There were no other changes to the composition of the Group during the current year under review save for the following:-

I. LYC Medical Center Sdn Bhd (“LYCMC”) and LYC Prostate Centre Sdn Bhd (“LYCPC”)

On 16 May 2024, LYC Dental & Aesthetic Holdings Sdn Bhd (“LYC D&A”), holding company of LYCMC and LYCPC, transfer 100% shareholding of LYCMC to HTAR Sdn Bhd (“HTAR”) and 100% shareholding of LYCPC to LYCMC. No change in intended principal activities of the companies.

II. Sigma Dental Laboratory Sdn. Bhd. (“Sigma Dental”)

LYC Dental Group Sdn Bhd (“LYCDG”), holding company of Sigma Dental, had on 2 August 2024, entered into a share sale agreement (“SSA”) with SPH Healthcare & Wellness Sdn Bhd (“SPH”) for the proposed acquisition by SPH of 600 ordinary shares in Sigma Dental, representing 60% equity interest in Sigma Dental, for a disposal consideration of RM380,000 to be satisfied entirely via cash.

The proposed disposal of Sigma Dental will enable the Group to realign business strategy and allowing the Group to concentrate on fewer operating entities and improve operational efficiency and effectiveness.

All the conditions precedent under the SSA have been fulfilled, and that the purchase consideration in accordance with the terms of the SSA has been satisfied to-date. Accordingly, the completion has taken place on 10 September 2024 and deconsolidated Sigma Dental from the Group’s result in accordance with MFRS 10.

A11 – Material Subsequent Events

Except as stated in note B7, there were no material event subsequent to the end of the current financial year under review.

A12 –Contingent Liabilities or Contingent Assets

The Group is not aware of any contingent liabilities incurred or known to be incurred which, upon becoming enforceable, may have a material impact on the financial results and financial position of the Group of companies, except for as follows:-

Specific indemnity pursuant to the share purchase agreement dated 1 March 2022 entered into between LYCM and KIB in respect of the divestment by LYCM of 6,532,500 LYCMS Shares (representing 25% equity interest in LYCMS) for a disposal consideration of SGD12,918,466 ("Disposal Consideration") ("SPA KIB").

Pursuant to the SPA KIB, LYCM unconditionally and irrevocably undertakes to KIB that in the event of an Qualifying IPO (i.e. listing of LYCMS Shares on the Catalist Board), if KIB elects (at its sole and absolute discretion) to sell or otherwise dispose, whether in the open market or through a private placement sale, in a single tranche or a series of tranches of sales or otherwise, all of the LYCMS Shares held by KIB as at the date of the put notice or in the event of an Qualifying IPO ("Option Shares") at any time within 24 calendar months from the Qualifying IPO approval date, LYCM shall, on demand, indemnify and reimburse KIB fully for any shortfall, i.e. Agreed Return less each and every sale price of the options shares received by LYCM. "Agreed Return" means the aggregate of (a) the Disposal Consideration, (b) 6% of the Disposal Consideration, and (c) in the event that the Option Shares are sold to LYCM, any and all brokerage fees and charges.

A13 – Capital Commitment

There is no capital commitment to the end of the current financial year under review, except for as follows:-

RM'000

Contracted but not provided for	11,368
---------------------------------	--------

11,368

A14 – Related Party Transaction

There were no related party transactions to the end of the current financial year under review, except for the following:

	Quarter ended 30-Sep-24 RM'000	Quarter ended 30-Sep-23 RM'000
Transactions with a Company which a director of a subsidiary has substantial financial interest		
Sales	-	4
	<hr/>	<hr/>
Transaction with a firm which a director is a sole proprietor		
Professional Fees	-	6
	<hr/>	<hr/>
Transactions with a Company which a major shareholder of the Company has substantial financial interest		
Payment on behalf of secondment of staff cost	32	-
	<hr/>	<hr/>

B1 – Financial Review of Performance

	Individual Period				Cumulative period			
	Current Quarter Ended	Preceding Year Corresponding Quarter Ended	Changes		Current Quarter Ended	Preceding Year Corresponding Quarter Ended	Changes	
	30-Sep-24	30-Sep-23	RM'000	%	30-Sep-24	30-Sep-23	RM'000	%
Revenue	41,735	32,401	9,334	29%	81,113	59,031	22,082	37%
Profit/(Loss) before tax (PBT/LBT)	1,549	(2,043)	3,592	-176%	821	(1,634)	2,455	-150%
Profit/(Loss) after tax (PAT/LAT)	426	(3,013)	3,439	-114%	(1,525)	(3,631)	2,106	-58%

Individual Period

The Group recorded a revenue of RM41.74 million for the second quarter ended 30 September 2024, compared to RM32.01 million recorded in the preceding year's corresponding quarter. The Group recorded profit before tax of RM1.55 million in the current quarter compared to a loss before tax of RM2.04 million in preceding year corresponding quarter. These reasons were due to the organic business growth from nutraceutical, clinical and confinement businesses as well as new subsidiaries acquired subsequent to Q2 FY2024.

Malaysia

The Malaysia segment generated a revenue of RM27.81 million in the current quarter ended 30 September 2024 compared to RM19.66 million in the quarter ended 30 September 2023.

The loss before tax for the current quarter ended 30 September 2024 was RM0.77 million compared to the loss before tax of RM3.51 million reported in the preceding year's corresponding quarter ended 30 September 2023. These reasons were due to better performance in confinement and nutraceutical businesses.

Singapore

Singapore's business generated a revenue of RM16.93 million and a profit before tax of RM1.39 million in the current quarter ended 30 September 2024 as compared to RM12.74 million and a profit before tax of RM1.47 million respectively in preceding year's corresponding quarter ended 30 September 2023. The reason was due to better performance in clinical business and a new clinic operated subsequent to Q2 FY2024.

B2 – Comparison with Preceding Quarter’s Results

	Current Quarter Ended 30-Sep-24	Preceding Quarter Ended 30-Jun-24	Changes	
	RM’000	RM’000	RM’000	%
Continuing operations				
Revenue	41,735	39,378	2,357	6%
Profit/(Loss) before tax (PBT/LBT)	1,549	(728)	2,277	-313%
Profit/(Loss) after tax (PAT/LAT)	426	(1,951)	2,377	-122%

On a quarter-on-quarter basis, the Group’s revenue stood at RM41.74 million compared to its immediate preceding quarter of RM39.38 million. The overall increase in revenue was mainly due to higher revenue from nutraceutical business.

In the current quarter ended 30 September 2024, the profit before tax was RM1.55 million compared to loss before tax of RM0.73 million recorded in the preceding quarter. The improvement from loss before tax to profit before tax was mainly due to the better performance from confinement and clinical businesses.

B3 – Current Year Prospects

Throughout this financial year, the Group will continue to grow clinical and nutraceutical business as well as optimising performance for other subsidiaries.

For long term growth, the Group will continue to actively pursue its development and expansion plans both domestically and abroad. The Group remains confident in its longer-term growth by improving our positioning in the growing healthcare markets and we will continue delivering encouraging performance in coming years through consolidation and execution of our committed business plans.

B4 – Profit Forecast

The Group did not publish any profit forecast in its Prospectus or in any public documents.

B5 – Profit from operations

Profit from operations after crediting/(charging):-

	Current Quarter		Cumulative Quarters	
	30-Sep-24	30-Sep-23	30-Sep-24	30-Sep-23
	RM'000	RM'000	RM'000	RM'000
Depreciation and amortisation	(3,286)	(3,441)	(8,107)	(6,164)
Net (provision) / reversal for slow moving inventories	86	(1)	-	(4)
Net unrealized foreign exchange (loss) / gain	327	18	34	(183)
Unwinding up discount on provision for restoration cost	(0)	(14)	(43)	(26)
Gain on disposal of a subsidiary	(235)	-	(235)	-

Save as above, there were no gain or loss on disposal of properties or plant and equipment, gain or loss on derivatives and exception items.

B6 – Taxation

	Current Quarter 30-Sep-24 RM'000	Cumulative Quarters 30-Sep-24 RM'000
Income tax:-		
- Current year	1,123	2,346

The above tax has arisen in absence of group tax relief.

B7 – Corporate Proposals

Save as disclosed below, there were no other corporate proposals announced or outstanding as at the date of this report.

I. Private Placement

30% of the Total Number of Issued Shares

On 8 June 2022, the Company had proposed to undertake a private placement of up to 30% of the total number of issued shares of LYC (“LYC Share(s)” or “Share(s)”).

On 19 September 2022, 80,000,000 Placement Shares issued pursuant to the Private Placement at price of RM0.1390 per unit.

On 3 October 2022, 3,000,000 Placement Shares issued pursuant to the Private Placement at price of RM0.166 per unit.

Bursa Securities had, vide its letter dated 10 January 2023, resolved to grant the Company an extension of time of 6 months from 30 November 2022 to 30 May 2023 to complete the implementation of the Private Placement.

On 28 March 2023, 56,000,000 Placement Shares issued pursuant to the Private Placement at price of RM0.21 per unit.

Purpose	Proceed Raised (RM'000)	Actual Utilisation (RM'000)	Remaining Balance (RM'000)	Intended Timeframe
Partial redemption of the outstanding redeemable non-cumulative preference shares ("RPS")	10,000	-	10,000	within 36 months
To part or fully finance business expansion/future viable investment	6,689	6,689	-	within 24 months
Working Capital	6,689	6,689	-	within 12 months
Total	23,378	13,378	10,000	

B7 – Corporate Proposals (cont'd)

II. Disposal of 55% Equity Shares in Elite Dental Team Sdn Bhd By LYC Dental & Aesthetic Holdings Sdn Bhd

On 1 October 2024, LYC Dental & Aesthetic Holdings Sdn Bhd ("LYC D&A" or the "Vendor"), a wholly-owned subsidiary of LYC, had entered into a share sale agreement ("SSA") with Dr. Wong Chew Weng ("Dr. Wong" or the "Purchaser") for the proposed disposal by LYC D&A of 178,200 ordinary shares in Elite Dental Team Sdn Bhd ("EDTSB") ("EDTSB Share(s)") ("Sale Share(s)"), representing its entire 55% equity interest in EDTSB, for a disposal consideration of RM6.50 million ("Disposal Consideration") to be satisfied entirely via cash, on the terms and conditions contained in the SSA ("Proposed Disposal").

The proposed disposal is expected to be completed by end of 2024.

III. Memorandum of Understanding entered between Aqurate Ingredients Intl (M) Sdn Bhd, Bereum Co Ltd and Hyundai C Square Co Ltd

On 9 August 2023, Aqurate Ingredients Intl (M) Sdn Bhd ("Aqurate"), a subsidiary of the Company had entered into a Memorandum of Understanding ("MOU") with Bereum Co Ltd ("Bereum") and Hyundai C Square Co Ltd ("HCSCCL") (collectively referred to as the "Parties") with the intention to confirm the mutual understandings among the Parties with regard to the postbiotics distribution and product development while expressing the Parties' common aim of reaching definitive agreements for the benefit of the Parties through mutual cooperation.

On 30 October 2024, Aqurate was appointed as the Exclusive Distributor via a Distribution Agreement with HCSCCL to set out the terms of the transaction.

IV. Memorandum of Understanding entered between LYC and LYC Wellness Sdn Bhd

On 29 September 2023, LYC had entered into a MOU with LYC Wellness Sdn Bhd with the intention to negotiate in good faith towards finalising and entering into a formal agreement with regards to the intention to lease part of the Medical and or Wellness Assets.

B8 – Borrowings

The Group's borrowings as at the end of the current financial year were as follows: -

	Current	Non-current
	RM'000	RM'000
Overdraft	9,995	-
Term loan (Secured)	46,292	23,381
	56,287	23,381

The Group has obtained an extension of the redemption of RPS 2 from the holder of the RPS 2 via a supplemental subscription agreement which will take effect on 2 September 2024 in the month of expiry of the tenure of the original subscription agreement. The new redemption date of the RPS 2 is 23 September 2025.

B9 – Material Litigations

There are no pending material litigations as at the date of this report.

B10 – Dividends

No dividend has been declared or paid during the current financial year under review.

B11 – Trade Receivables

The ageing analysis of the Group's trade receivables is as follows: -

	30-Sep-24
	(RM'000)
Not past due	2,217
Past due	
- less than 3 months	7,026
- 3 to 6 months	1,505
- over 6 months	1,295
	9,826
	12,043

Receivables that are past due but not impaired

The Group believes that no further impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.

B12 – Loss per Share (“LPS”)

	Current Quarter Ended		Cumulative Quarters Ended	
	30-Sep-24	30-Sep-23	30-Sep-24	30-Sep-23
Loss for the period attributable to owners of company (RM'000)	(2,768)	(4,244)	(6,190)	(6,440)
Weighted average number of ordinary shares in issue ('000)	658,784	649,978	658,784	649,978
Basic LPS (sen)	(0.42)	(0.65)	(0.94)	(0.99)

a) Basic loss per share

Basic LPS of the Group is calculated by dividing the loss for the period attributable to ordinary equity holders of LYC by the weighted average number of ordinary shares in issue during the financial period.

The weighted average number of ordinary shares in issue is determined using the number of days that the specific shares are outstanding in proportion to the total number of days in the corresponding period.

b) Diluted LPS

The Company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial year to date.

B13 – Approval for the Release of Quarterly Results

The quarterly financial results have been approved for release by the Board of Directors.